Drug Profile
Research programme: eye disorder therapies - Envisia Therapeutics
Alternative Names: Controlled-release bevacizumab intravitreal implant - Envisia; Dexamethasone ophthalmic - Envisia Therapeutics; Dexamethasone ophthalmic - Liquidia Technologies; Difluprednate ophthalmic - Envisia Therapeutics; Difluprednate ophthalmic - Liquidia Technologies; ENV 1305; ENV 705; ENV 905; Extended release anti-VEGF therapy - Envisia; Extended-release bevacizumab - Envisia; Research programme: eye disorder therapies - Liquidia TechnologiesLatest Information Update: 16 Feb 2023
Price :
$50
*
At a glance
- Originator Liquidia Technologies
- Developer Envisia Therapeutics
- Class Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Prostaglandins; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists; Steroid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Eye disorders; Postoperative inflammation; Postoperative pain; Wet age-related macular degeneration
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for preclinical development in Eye-disorders in USA (Ophthalmic, Controlled release)
- 28 Nov 2021 No recent reports of development identified for preclinical development in Eye-disorders in USA (Topical, Drops)
- 28 Oct 2019 No recent reports of development identified for preclinical development in Postoperative-inflammation in USA (Ophthalmic, Implant)